A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Kardigan, Inc.
- Study ID
- NCT07771465
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Danicamtiv — DRUGDanicamtiv will be administered twice daily for up to 5 years
Study Details
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.
Key Dates
- First listed
- Aug 18, 2026
- Start date
- Aug 26, 2026
- Status verified
- Aug 2026
- Primary completion
- Nov 30, 2032
- Completion
- Jan 31, 2033
Study Design
- Enrollment
- 332 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Danicamtiv
Primary Outcome Measure
Frequency and severity of treatment-emergent adverse events (TEAEs) [ Time Frame: 61 months ]
Central Contacts
- Kardigan Clinical Trial Information Team1-877-310-5135
Locations (28)
Find similar trials in Birmingham, AL
By research site
University of Alabama Birmingham· Birmingham, ALCedars Sinai· Los Angeles, CAUniversity of California, Los Angeles (UCLA) - David Geffen School of Medicine· Los Angeles, CAUniversity of California, San Diego (UCSD) - Medical Center· San Diego, CAUniversity of California, San Francisco (UCSF)· San Francisco, CAStanford University Medical Center· Stanford, CA